Voyager Therapeutics, Inc. entered into a Collaboration and License Agreement with Neurocrine Biosciences, Inc. for the research, development and commercialization of adeno-associated virus (“AAV”)-based gene therapy products. Under the Collaboration Agreement, upon the expiration or termination of applicable waiting periods and the receipt of any required approvals or clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (such date, the “Effective Date” and such clearance, “Antitrust Clearance”), the company and Neurocrine have agreed to collaborate on the conduct of four collaboration programs: the company's VY-AADC program, intended to advance the Company's VY-AADC product candidate for the treatment of Parkinson's disease, which is currently in an ongoing Phase 2 trial; the company's program intended to generate gene therapy product candidates for the treatment of Friedreich's ataxia, including the Company's VY-FXN01 product candidate (the “FA Program” and, collectively with the AADC Program, the “Existing Programs”); and two programs to be determined by the Company and Neurocrine at a later date. Under the terms of the Collaboration Agreement, subject to the rights retained by the Company thereunder, the Company has agreed to collaborate with Neurocrine on, and to grant, as of the Effective Date, exclusive, royalty-bearing, non-transferable, sublicensable licenses to certain of the Company's intellectual property rights, for all human and veterinary diagnostic, prophylactic, and therapeutic uses, for the research, development, and commercialization of gene therapy products under the AADC Program, on a worldwide basis; the FA program, in the United States and, upon expiration of Sanofi Genzyme's option to the FA Program pursuant to its ongoing collaboration with the company without exercise of such option, all countries in the world in which the Collaboration Agreement remained in effect with respect to the FA Program; and each Discovery Program, on a worldwide basis.